miR-200c increases the sensitivity of breast cancer cells to Doxorubicin through downregulating MDR1 gene
Breast cancer (BC) has been known as the most common type of cancer worldwide and resulted in death among women. BC is usually resistant to standard therapies that are significant problems in managing BC patients. miR-200c belongs to the miRNA family, which is considered as a tumor suppressor with r...
Saved in:
| Published in | Experimental and molecular pathology Vol. 125; p. 104753 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Inc
01.04.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0014-4800 1096-0945 1096-0945 |
| DOI | 10.1016/j.yexmp.2022.104753 |
Cover
| Abstract | Breast cancer (BC) has been known as the most common type of cancer worldwide and resulted in death among women. BC is usually resistant to standard therapies that are significant problems in managing BC patients. miR-200c belongs to the miRNA family, which is considered as a tumor suppressor with reduced expression levels in various kinds of cancer like BC. Increased expression of miR-200c has been reported as a potent inhibitor of drug resistance and tumor advancement. The purpose of this paper is to examine the outcome of miR-200c restoring on enhancing the BC cells' sensitivity to Doxorubicin through downregulating the MDR1 expression.
Initially, MDA-MB-231 cells were transfected with miR-200c to perform functional analyses. After that, MTT assay was performed to investigate the viability of the cell. Finally, qRT-PCR was used to assess gene expression.
According to the results, the miR-200c expression was downregulated in BC cells compared to control. Moreover, the cell viability was reduced in transfected cells via regulation in gene expression associated with apoptosis. Furthermore, miR-200c could increase the BC cells' sensitivity to Doxorubicin by reducing the MDR1 gene expression.
Hence, this study's findings recommend that miR-200c can consider as a method of therapy for the treatment of BC. |
|---|---|
| AbstractList | Breast cancer (BC) has been known as the most common type of cancer worldwide and resulted in death among women. BC is usually resistant to standard therapies that are significant problems in managing BC patients. miR-200c belongs to the miRNA family, which is considered as a tumor suppressor with reduced expression levels in various kinds of cancer like BC. Increased expression of miR-200c has been reported as a potent inhibitor of drug resistance and tumor advancement. The purpose of this paper is to examine the outcome of miR-200c restoring on enhancing the BC cells' sensitivity to Doxorubicin through downregulating the MDR1 expression.BACKGROUNDBreast cancer (BC) has been known as the most common type of cancer worldwide and resulted in death among women. BC is usually resistant to standard therapies that are significant problems in managing BC patients. miR-200c belongs to the miRNA family, which is considered as a tumor suppressor with reduced expression levels in various kinds of cancer like BC. Increased expression of miR-200c has been reported as a potent inhibitor of drug resistance and tumor advancement. The purpose of this paper is to examine the outcome of miR-200c restoring on enhancing the BC cells' sensitivity to Doxorubicin through downregulating the MDR1 expression.Initially, MDA-MB-231 cells were transfected with miR-200c to perform functional analyses. After that, MTT assay was performed to investigate the viability of the cell. Finally, qRT-PCR was used to assess gene expression.METHODSInitially, MDA-MB-231 cells were transfected with miR-200c to perform functional analyses. After that, MTT assay was performed to investigate the viability of the cell. Finally, qRT-PCR was used to assess gene expression.According to the results, the miR-200c expression was downregulated in BC cells compared to control. Moreover, the cell viability was reduced in transfected cells via regulation in gene expression associated with apoptosis. Furthermore, miR-200c could increase the BC cells' sensitivity to Doxorubicin by reducing the MDR1 gene expression.RESULTSAccording to the results, the miR-200c expression was downregulated in BC cells compared to control. Moreover, the cell viability was reduced in transfected cells via regulation in gene expression associated with apoptosis. Furthermore, miR-200c could increase the BC cells' sensitivity to Doxorubicin by reducing the MDR1 gene expression.Hence, this study's findings recommend that miR-200c can consider as a method of therapy for the treatment of BC.CONCLUSIONHence, this study's findings recommend that miR-200c can consider as a method of therapy for the treatment of BC. Breast cancer (BC) has been known as the most common type of cancer worldwide and resulted in death among women. BC is usually resistant to standard therapies that are significant problems in managing BC patients. miR-200c belongs to the miRNA family, which is considered as a tumor suppressor with reduced expression levels in various kinds of cancer like BC. Increased expression of miR-200c has been reported as a potent inhibitor of drug resistance and tumor advancement. The purpose of this paper is to examine the outcome of miR-200c restoring on enhancing the BC cells' sensitivity to Doxorubicin through downregulating the MDR1 expression. Initially, MDA-MB-231 cells were transfected with miR-200c to perform functional analyses. After that, MTT assay was performed to investigate the viability of the cell. Finally, qRT-PCR was used to assess gene expression. According to the results, the miR-200c expression was downregulated in BC cells compared to control. Moreover, the cell viability was reduced in transfected cells via regulation in gene expression associated with apoptosis. Furthermore, miR-200c could increase the BC cells' sensitivity to Doxorubicin by reducing the MDR1 gene expression. Hence, this study's findings recommend that miR-200c can consider as a method of therapy for the treatment of BC. |
| ArticleNumber | 104753 |
| Author | Najjary, Shiva Bolandi, Nadia Amini, Mohammad Alizadeh, Nazila Saeedi, Hossein Baradaran, Behzad Javadrashid, Darya Mokhtarzadeh, Ahad Safaei, Sahar |
| Author_xml | – sequence: 1 givenname: Sahar surname: Safaei fullname: Safaei, Sahar – sequence: 2 givenname: Mohammad surname: Amini fullname: Amini, Mohammad – sequence: 3 givenname: Shiva surname: Najjary fullname: Najjary, Shiva – sequence: 4 givenname: Ahad surname: Mokhtarzadeh fullname: Mokhtarzadeh, Ahad – sequence: 5 givenname: Nadia surname: Bolandi fullname: Bolandi, Nadia – sequence: 6 givenname: Hossein surname: Saeedi fullname: Saeedi, Hossein – sequence: 7 givenname: Nazila surname: Alizadeh fullname: Alizadeh, Nazila – sequence: 8 givenname: Darya surname: Javadrashid fullname: Javadrashid, Darya – sequence: 9 givenname: Behzad surname: Baradaran fullname: Baradaran, Behzad email: baradaranb@tbzmed.ac.ir |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35235816$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkcFu1DAQhi1URLeFJ0BCPnLJMraTbHzggFqglYoqVXC2bGey9SqxF9tpu2-Pt1s4cGhPlsbfNxr9_wk58sEjIe8ZLBmw9tNmucOHabvkwHmZ1KtGvCILBrKtQNbNEVkAsLqqO4BjcpLSBgAkMP6GHIuGi6Zj7YK4yd1UHMBS521EnTDRfIs0oU8uuzuXdzQM1Oy_MrXaW4zU4jgWLNDz8BDibJx1vlgxzOtb2od7H3E9jzo7v6Y_zm8YXaPHt-T1oMeE757eU_Lr29efZxfV1fX3y7MvV5UVjcyVHFYdH7BveuhEb4euazmrje5aJow0oI0FITiirI2QrUDbMG2Z0YC25YMUp-TjYe82ht8zpqwml_YXa49hToq3oqlXNQhW0A9P6Gwm7NU2uknHnfobTwHEAbAxpBRx-IcwUPsS1EY9lqD2JahDCcWS_1nW5ZJG8DlqN77gfj64WCK6cxhVsg5L6r2LaLPqg3vW_wNHCKQo |
| CitedBy_id | crossref_primary_10_1007_s12079_023_00789_0 crossref_primary_10_1007_s11033_024_10007_8 crossref_primary_10_1016_j_genrep_2024_101886 crossref_primary_10_1038_s41568_023_00612_3 crossref_primary_10_1038_s41598_023_49225_8 crossref_primary_10_3390_life14121546 crossref_primary_10_3389_fphar_2024_1486783 crossref_primary_10_1371_journal_pone_0307420 crossref_primary_10_3389_fimmu_2024_1425602 crossref_primary_10_3892_br_2024_1872 crossref_primary_10_3390_genes14071375 crossref_primary_10_20517_cdr_2023_19 crossref_primary_10_1155_2022_6899777 crossref_primary_10_3390_biomedicines11113007 crossref_primary_10_7759_cureus_65027 crossref_primary_10_1016_j_bioactmat_2024_10_011 crossref_primary_10_1007_s00210_024_03719_y crossref_primary_10_3390_cells11061008 crossref_primary_10_3892_ol_2024_14314 |
| Cites_doi | 10.1007/s00109-016-1420-5 10.1016/j.ajpath.2012.07.009 10.1111/pcmr.12379 10.1002/jcb.25162 10.1006/meth.2001.1262 10.18632/oncotarget.18028 10.1002/gcc.22422 10.1038/srep15906 10.1007/s10549-015-3305-7 10.2174/2211738507666190122111224 10.1016/j.biopha.2016.09.099 10.1111/1440-1681.13307 10.2147/OTT.S152462 10.1186/s12885-015-1238-5 10.1158/1078-0432.CCR-13-1326 10.1371/journal.pone.0050469 10.1016/j.biopha.2016.11.100 10.1007/s12253-017-0222-6 10.1002/jcp.28823 10.1158/1541-7786.MCR-10-0052 10.1002/mc.21864 10.1038/onc.2015.48 10.7150/thno.29380 10.3322/caac.21583 10.1038/cr.2011.62 10.1084/jem.20110235 10.1016/j.ejphar.2018.09.024 10.1007/s11864-019-0685-7 10.1038/s41417-018-0035-0 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.yexmp.2022.104753 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry |
| EISSN | 1096-0945 |
| ExternalDocumentID | 35235816 10_1016_j_yexmp_2022_104753 S0014480022000132 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA GROUPED_DOAJ HDY HLW HMK HMO HVGLF HZ~ IHE J1W K-O KOM L7B LCYCR LG5 LX2 M29 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SBG SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K UHS UNMZH WUQ X7M XPP ZGI ZMT ZU3 ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO ADVLN AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
| ID | FETCH-LOGICAL-c359t-9f782fed5d083dcf886214ba8613b9b0abc0332ee94b3963ec51ac1ba0ec62f93 |
| IEDL.DBID | AIKHN |
| ISSN | 0014-4800 1096-0945 |
| IngestDate | Thu Sep 04 19:11:09 EDT 2025 Thu Apr 03 07:08:22 EDT 2025 Tue Jul 01 01:56:51 EDT 2025 Thu Apr 24 23:04:49 EDT 2025 Fri Feb 23 02:41:43 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Chemosensitivity MDR1 Breast cancer miR-200c Doxorubicin |
| Language | English |
| License | Copyright © 2022 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c359t-9f782fed5d083dcf886214ba8613b9b0abc0332ee94b3963ec51ac1ba0ec62f93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 35235816 |
| PQID | 2635474031 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2635474031 pubmed_primary_35235816 crossref_primary_10_1016_j_yexmp_2022_104753 crossref_citationtrail_10_1016_j_yexmp_2022_104753 elsevier_sciencedirect_doi_10_1016_j_yexmp_2022_104753 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | April 2022 2022-04-00 20220401 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 04 year: 2022 text: April 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Experimental and molecular pathology |
| PublicationTitleAlternate | Exp Mol Pathol |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Ghasabi, Majidi, Mansoori, Mohammadi, Shomali, Shirafkan, Baghbani, Kazemi, Baradaran (bb0035) 2019; 234 Kim, Veronese, Pichiorri, Lee, Jeon, Volinia, Pineau, Marchio, Palatini, Suh (bb0060) 2011; 208 Tormo, Pineda, Serna, Guijarro, Ribas, Fores, Chirivella, Climent, Lluch, Eroles (bb0140) 2015; 116 Liu, Tetzlaff, Cui, Xu (bb0075) 2012; 181 Mohammadi, Mansoori, Baradaran (bb0100) 2016; 84 Yang, Li, Li, Ruan, Quan (bb0150) 2018; 17 Rossi, Mazzara, Pagani (bb0120) 2019; 20 Knezevic, Pfefferle, Petrovic, Greene, Perou, Rosen (bb0065) 2015; 34 Heydari, Saidijam, Reza Sharifi, Asl, Shabab, Najafi (bb0040) 2018; 24 Zhang, Ge, Wang, Xu, Guo, Xu (bb0155) 2019; 23 Mi, Wang, Wang, Li, Zhu, Wang, Xiong, Gu (bb0095) 2018; 839 Karakatsanis, Papaconstantinou, Gazouli, Lyberopoulou, Polymeneas, Voros (bb0055) 2013; 52 Tang, Deng, Tang, Xie, Guo, Kong, Ye, Su, Xie (bb0135) 2013; 19 Wu, Zhang, Lu, Bo, Li, Wang, Zhang, Mao (bb0145) 2019; 26 Qian, Howell, Li, Qin, Gao, Xi (bb0110) 2010 Damiano, Brisotto, Borgna, di Gennaro, Armellin, Perin, Guardascione, Maestro, Santarosa (bb0020) 2017; 56 Hu, Tan, He, Zhang, Xu, Tang (bb0045) 2018; 11 Seong, Lee, Byeon, Sohn, Seol, Lee, Kim, Kim, Noh (bb0130) 2015; 150 Kopp, Oak, Wagner, Roidl (bb0070) 2012; 7 Liu, Du, Zhou, Xu, Chen, Chen, Yang, Liu, Shao, Zhang (bb0085) 2018; 8 Chen, Tian, He, Chen, Huang, Wang, Chen (bb0015) 2018; 40 Liu, Tetzlaff, Wang, Yang, Xie, Zhang, Krepler, Xiao, Beqiri, Xu (bb0080) 2015; 28 Livak, Schmittgen (bb0090) 2001; 25 Mutlu, Raza, Saatci, Eyüpoğlu, Yurdusev, Şahin (bb0105) 2016; 94 DeSantis, Ma, Gaudet, Newman, Miller, Goding Sauer, Jemal, Siegel (bb0025) 2019; 69 Fisusi, Akala (bb0030) 2019; 7 Schubert, Brabletz (bb0125) 2011; 21 Jing, Xiong, Li, Wu, Zhou, Gui, Mei (bb0050) 2015; 5 Zhou, Zhang, Guo, Huang, Xie, Yue, Chen, Jiang, Li (bb0165) 2017; 85 Zhang, Wang, Xiang, Huang, Zhou (bb0160) 2020; 47 Rizzo, Cangemi, Galvano, Fanale, Buscemi, Ciaccio, Russo, Castorina, Bazan (bb0115) 2017; 8 Antolín, Calvo, Blanco-Calvo, Santiago, Lorenzo-Patiño, Haz-Conde, Santamarina, Figueroa, Antón-Aparicio, Valladares-Ayerbes (bb0005) 2015; 15 Ceppi, Mudduluru, Kumarswamy, Rapa, Scagliotti, Papotti, Allgayer (bb0010) 2010; 8 Karakatsanis (10.1016/j.yexmp.2022.104753_bb0055) 2013; 52 Mutlu (10.1016/j.yexmp.2022.104753_bb0105) 2016; 94 Damiano (10.1016/j.yexmp.2022.104753_bb0020) 2017; 56 Antolín (10.1016/j.yexmp.2022.104753_bb0005) 2015; 15 Chen (10.1016/j.yexmp.2022.104753_bb0015) 2018; 40 Knezevic (10.1016/j.yexmp.2022.104753_bb0065) 2015; 34 Mohammadi (10.1016/j.yexmp.2022.104753_bb0100) 2016; 84 Liu (10.1016/j.yexmp.2022.104753_bb0075) 2012; 181 Mi (10.1016/j.yexmp.2022.104753_bb0095) 2018; 839 Fisusi (10.1016/j.yexmp.2022.104753_bb0030) 2019; 7 Rizzo (10.1016/j.yexmp.2022.104753_bb0115) 2017; 8 Zhou (10.1016/j.yexmp.2022.104753_bb0165) 2017; 85 DeSantis (10.1016/j.yexmp.2022.104753_bb0025) 2019; 69 Zhang (10.1016/j.yexmp.2022.104753_bb0160) 2020; 47 Qian (10.1016/j.yexmp.2022.104753_bb0110) 2010 Kim (10.1016/j.yexmp.2022.104753_bb0060) 2011; 208 Wu (10.1016/j.yexmp.2022.104753_bb0145) 2019; 26 Livak (10.1016/j.yexmp.2022.104753_bb0090) 2001; 25 Liu (10.1016/j.yexmp.2022.104753_bb0080) 2015; 28 Rossi (10.1016/j.yexmp.2022.104753_bb0120) 2019; 20 Ghasabi (10.1016/j.yexmp.2022.104753_bb0035) 2019; 234 Kopp (10.1016/j.yexmp.2022.104753_bb0070) 2012; 7 Schubert (10.1016/j.yexmp.2022.104753_bb0125) 2011; 21 Seong (10.1016/j.yexmp.2022.104753_bb0130) 2015; 150 Yang (10.1016/j.yexmp.2022.104753_bb0150) 2018; 17 Liu (10.1016/j.yexmp.2022.104753_bb0085) 2018; 8 Tang (10.1016/j.yexmp.2022.104753_bb0135) 2013; 19 Tormo (10.1016/j.yexmp.2022.104753_bb0140) 2015; 116 Hu (10.1016/j.yexmp.2022.104753_bb0045) 2018; 11 Zhang (10.1016/j.yexmp.2022.104753_bb0155) 2019; 23 Ceppi (10.1016/j.yexmp.2022.104753_bb0010) 2010; 8 Heydari (10.1016/j.yexmp.2022.104753_bb0040) 2018; 24 Jing (10.1016/j.yexmp.2022.104753_bb0050) 2015; 5 |
| References_xml | – volume: 23 start-page: 7209 year: 2019 end-page: 7216 ident: bb0155 article-title: MiR-200c regulates apoptosis of placental trophoblasts in preeclampsia rats through Wnt/β-catenin signaling pathway publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 8 start-page: 1207 year: 2010 end-page: 1216 ident: bb0010 article-title: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non–small cell lung cancer publication-title: Mol. Cancer Res. – volume: 7 year: 2012 ident: bb0070 article-title: miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression publication-title: PLoS One – volume: 20 start-page: 1 year: 2019 end-page: 14 ident: bb0120 article-title: Diagnosis and treatment of breast cancer in young women publication-title: Curr. Treat. Options in Oncol. – volume: 150 start-page: 141 year: 2015 end-page: 148 ident: bb0130 article-title: Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer publication-title: Breast Cancer Res. Treat. – volume: 69 start-page: 438 year: 2019 end-page: 451 ident: bb0025 article-title: Breast cancer statistics, 2019 publication-title: CA Cancer J. Clin. – volume: 34 start-page: 5997 year: 2015 end-page: 6006 ident: bb0065 article-title: Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential publication-title: Oncogene – volume: 8 start-page: 71924 year: 2017 ident: bb0115 article-title: Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin publication-title: Oncotarget – volume: 52 start-page: 297 year: 2013 end-page: 303 ident: bb0055 article-title: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance publication-title: Mol. Carcinog. – volume: 234 start-page: 22581 year: 2019 end-page: 22592 ident: bb0035 article-title: The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration publication-title: J. Cell. Physiol. – volume: 5 start-page: 1 year: 2015 end-page: 12 ident: bb0050 article-title: A feedback regulatory loop involving p53/miR-200 and growth hormone endocrine axis controls embryo size of zebrafish publication-title: Sci. Rep. – volume: 40 start-page: 3821 year: 2018 end-page: 3829 ident: bb0015 article-title: Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2 publication-title: Oncol. Rep. – volume: 208 start-page: 875 year: 2011 end-page: 883 ident: bb0060 article-title: p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2 publication-title: J. Exp. Med. – year: 2010 ident: bb0110 article-title: MiR-200c Sensitizes Colorectal cancer Cells to 5-FU through Bcl-2-Involved Apoptotic Pathway – volume: 7 start-page: 3 year: 2019 end-page: 23 ident: bb0030 article-title: Drug combinations in breast cancer therapy publication-title: Pharm. Nanotechnol. – volume: 181 start-page: 1823 year: 2012 end-page: 1835 ident: bb0075 article-title: miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1 publication-title: Am. J. Pathol. – volume: 21 start-page: 705 year: 2011 end-page: 707 ident: bb0125 article-title: p53 spreads out further: suppression of EMT and stemness by activating miR-200c expression publication-title: Cell Res. – volume: 94 start-page: 629 year: 2016 end-page: 644 ident: bb0105 article-title: miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance publication-title: J. Mol. Med. – volume: 15 start-page: 1 year: 2015 end-page: 15 ident: bb0005 article-title: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer publication-title: BMC Cancer – volume: 24 start-page: 145 year: 2018 end-page: 151 ident: bb0040 article-title: The effect of miR-200c inhibition on chemosensitivity (5-FluoroUracil) in colorectal cancer publication-title: Pathol. Oncol. Res. – volume: 839 start-page: 66 year: 2018 end-page: 75 ident: bb0095 article-title: miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN publication-title: Eur. J. Pharmacol. – volume: 25 start-page: 402 year: 2001 end-page: 408 ident: bb0090 article-title: Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method publication-title: Methods – volume: 11 start-page: 1529 year: 2018 ident: bb0045 article-title: Functional miRNAs in breast cancer drug resistance publication-title: Onco. Targets. Ther. – volume: 17 start-page: 6211 year: 2018 end-page: 6226 ident: bb0150 article-title: Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis publication-title: Mol. Med. Rep. – volume: 56 start-page: 147 year: 2017 end-page: 158 ident: bb0020 article-title: Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1 publication-title: Genes Chromosom. Cancer – volume: 116 start-page: 2061 year: 2015 end-page: 2073 ident: bb0140 article-title: MicroRNA profile in response to doxorubicin treatment in breast cancer publication-title: J. Cell. Biochem. – volume: 47 start-page: 1464 year: 2020 end-page: 1472 ident: bb0160 article-title: LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN publication-title: Clin. Exp. Pharmacol. Physiol. – volume: 84 start-page: 705 year: 2016 end-page: 713 ident: bb0100 article-title: The role of microRNAs in colorectal cancer publication-title: Biomed. Pharmacother. – volume: 8 start-page: 5801 year: 2018 ident: bb0085 article-title: miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis publication-title: Theranostics – volume: 28 start-page: 431 year: 2015 end-page: 441 ident: bb0080 article-title: miR-200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment publication-title: Pigment Cell Melanoma Res. – volume: 26 start-page: 74 year: 2019 end-page: 82 ident: bb0145 article-title: miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1 publication-title: Cancer Gene Ther. – volume: 85 start-page: 113 year: 2017 end-page: 119 ident: bb0165 article-title: miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1 publication-title: Biomed. Pharmacother. – volume: 19 start-page: 5602 year: 2013 end-page: 5612 ident: bb0135 article-title: miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression publication-title: Clin. Cancer Res. – volume: 94 start-page: 629 year: 2016 ident: 10.1016/j.yexmp.2022.104753_bb0105 article-title: miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance publication-title: J. Mol. Med. doi: 10.1007/s00109-016-1420-5 – volume: 181 start-page: 1823 year: 2012 ident: 10.1016/j.yexmp.2022.104753_bb0075 article-title: miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1 publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2012.07.009 – volume: 28 start-page: 431 year: 2015 ident: 10.1016/j.yexmp.2022.104753_bb0080 article-title: miR-200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment publication-title: Pigment Cell Melanoma Res. doi: 10.1111/pcmr.12379 – volume: 116 start-page: 2061 year: 2015 ident: 10.1016/j.yexmp.2022.104753_bb0140 article-title: MicroRNA profile in response to doxorubicin treatment in breast cancer publication-title: J. Cell. Biochem. doi: 10.1002/jcb.25162 – volume: 25 start-page: 402 year: 2001 ident: 10.1016/j.yexmp.2022.104753_bb0090 article-title: Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method publication-title: Methods doi: 10.1006/meth.2001.1262 – volume: 8 start-page: 71924 year: 2017 ident: 10.1016/j.yexmp.2022.104753_bb0115 article-title: Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin publication-title: Oncotarget doi: 10.18632/oncotarget.18028 – volume: 40 start-page: 3821 year: 2018 ident: 10.1016/j.yexmp.2022.104753_bb0015 article-title: Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2 publication-title: Oncol. Rep. – year: 2010 ident: 10.1016/j.yexmp.2022.104753_bb0110 – volume: 56 start-page: 147 year: 2017 ident: 10.1016/j.yexmp.2022.104753_bb0020 article-title: Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1 publication-title: Genes Chromosom. Cancer doi: 10.1002/gcc.22422 – volume: 5 start-page: 1 year: 2015 ident: 10.1016/j.yexmp.2022.104753_bb0050 article-title: A feedback regulatory loop involving p53/miR-200 and growth hormone endocrine axis controls embryo size of zebrafish publication-title: Sci. Rep. doi: 10.1038/srep15906 – volume: 150 start-page: 141 year: 2015 ident: 10.1016/j.yexmp.2022.104753_bb0130 article-title: Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-015-3305-7 – volume: 7 start-page: 3 year: 2019 ident: 10.1016/j.yexmp.2022.104753_bb0030 article-title: Drug combinations in breast cancer therapy publication-title: Pharm. Nanotechnol. doi: 10.2174/2211738507666190122111224 – volume: 84 start-page: 705 year: 2016 ident: 10.1016/j.yexmp.2022.104753_bb0100 article-title: The role of microRNAs in colorectal cancer publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2016.09.099 – volume: 47 start-page: 1464 year: 2020 ident: 10.1016/j.yexmp.2022.104753_bb0160 article-title: LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN publication-title: Clin. Exp. Pharmacol. Physiol. doi: 10.1111/1440-1681.13307 – volume: 11 start-page: 1529 year: 2018 ident: 10.1016/j.yexmp.2022.104753_bb0045 article-title: Functional miRNAs in breast cancer drug resistance publication-title: Onco. Targets. Ther. doi: 10.2147/OTT.S152462 – volume: 15 start-page: 1 year: 2015 ident: 10.1016/j.yexmp.2022.104753_bb0005 article-title: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer publication-title: BMC Cancer doi: 10.1186/s12885-015-1238-5 – volume: 19 start-page: 5602 year: 2013 ident: 10.1016/j.yexmp.2022.104753_bb0135 article-title: miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-1326 – volume: 17 start-page: 6211 year: 2018 ident: 10.1016/j.yexmp.2022.104753_bb0150 article-title: Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis publication-title: Mol. Med. Rep. – volume: 7 year: 2012 ident: 10.1016/j.yexmp.2022.104753_bb0070 article-title: miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression publication-title: PLoS One doi: 10.1371/journal.pone.0050469 – volume: 85 start-page: 113 year: 2017 ident: 10.1016/j.yexmp.2022.104753_bb0165 article-title: miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1 publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2016.11.100 – volume: 24 start-page: 145 year: 2018 ident: 10.1016/j.yexmp.2022.104753_bb0040 article-title: The effect of miR-200c inhibition on chemosensitivity (5-FluoroUracil) in colorectal cancer publication-title: Pathol. Oncol. Res. doi: 10.1007/s12253-017-0222-6 – volume: 234 start-page: 22581 year: 2019 ident: 10.1016/j.yexmp.2022.104753_bb0035 article-title: The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration publication-title: J. Cell. Physiol. doi: 10.1002/jcp.28823 – volume: 8 start-page: 1207 year: 2010 ident: 10.1016/j.yexmp.2022.104753_bb0010 article-title: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non–small cell lung cancer publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-10-0052 – volume: 52 start-page: 297 year: 2013 ident: 10.1016/j.yexmp.2022.104753_bb0055 article-title: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance publication-title: Mol. Carcinog. doi: 10.1002/mc.21864 – volume: 34 start-page: 5997 year: 2015 ident: 10.1016/j.yexmp.2022.104753_bb0065 article-title: Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential publication-title: Oncogene doi: 10.1038/onc.2015.48 – volume: 8 start-page: 5801 year: 2018 ident: 10.1016/j.yexmp.2022.104753_bb0085 article-title: miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis publication-title: Theranostics doi: 10.7150/thno.29380 – volume: 23 start-page: 7209 year: 2019 ident: 10.1016/j.yexmp.2022.104753_bb0155 article-title: MiR-200c regulates apoptosis of placental trophoblasts in preeclampsia rats through Wnt/β-catenin signaling pathway publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 69 start-page: 438 year: 2019 ident: 10.1016/j.yexmp.2022.104753_bb0025 article-title: Breast cancer statistics, 2019 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21583 – volume: 21 start-page: 705 year: 2011 ident: 10.1016/j.yexmp.2022.104753_bb0125 article-title: p53 spreads out further: suppression of EMT and stemness by activating miR-200c expression publication-title: Cell Res. doi: 10.1038/cr.2011.62 – volume: 208 start-page: 875 year: 2011 ident: 10.1016/j.yexmp.2022.104753_bb0060 article-title: p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2 publication-title: J. Exp. Med. doi: 10.1084/jem.20110235 – volume: 839 start-page: 66 year: 2018 ident: 10.1016/j.yexmp.2022.104753_bb0095 article-title: miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2018.09.024 – volume: 20 start-page: 1 year: 2019 ident: 10.1016/j.yexmp.2022.104753_bb0120 article-title: Diagnosis and treatment of breast cancer in young women publication-title: Curr. Treat. Options in Oncol. doi: 10.1007/s11864-019-0685-7 – volume: 26 start-page: 74 year: 2019 ident: 10.1016/j.yexmp.2022.104753_bb0145 article-title: miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1 publication-title: Cancer Gene Ther. doi: 10.1038/s41417-018-0035-0 |
| SSID | ssj0009012 |
| Score | 2.4226406 |
| Snippet | Breast cancer (BC) has been known as the most common type of cancer worldwide and resulted in death among women. BC is usually resistant to standard therapies... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 104753 |
| SubjectTerms | ATP Binding Cassette Transporter, Subfamily B - genetics Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Cell Line, Tumor Chemosensitivity Doxorubicin Doxorubicin - pharmacology Female Gene Expression Regulation, Neoplastic Humans MDR1 MicroRNAs - genetics miR-200c |
| Title | miR-200c increases the sensitivity of breast cancer cells to Doxorubicin through downregulating MDR1 gene |
| URI | https://dx.doi.org/10.1016/j.yexmp.2022.104753 https://www.ncbi.nlm.nih.gov/pubmed/35235816 https://www.proquest.com/docview/2635474031 |
| Volume | 125 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbKVgIuFZTXUloZiSOh8SPZ-FhtqRZW28OKit4s27GlVDSp9iGVC7-dmdgp4tAeeorycGLNjGa-icffEPLJ13luVMEzq4TMpAhlZioRMumtLKxUvu57Ay7Oy9mF_H5ZXO6Q6bAXBssqk--PPr331unKcZLm8U3T4B5fSAYQ7_AeyIAf3uVClcWI7J58m8_O_3Hv5iyShjOYDQwYyIf6Mq_f_vYaeSs5x-XOSSHuC1D3AdA-EJ29IHsJQdKTOMmXZMe3--TZdGjctk-eLtJ6-SvSXDdLtFBHmxbh4dqvKSA-usay9dg3gnaBWry1oQ4tYEXxXz481tHT7rZbbS2-i6Z-PrSGrH0V-9dD0KOL0yWjYIP-Nbk4-_pjOstSc4XMiUJtMhUAGwRfFzWAsNqFClIbJq2pIL5bZXNjXS4E915JC1IV3hXMOGZN7l3JgxJvyKjtWv-OUOVqVgXDWV1bKS3k6iqXQRrmXTUJpRkTPkhUu8Q8jg0wfumhxOxK92rQqAYd1TAmn-8G3UTijYcfLwdV6f_sR0NoeHjgx0GxGvSEIjat77ZrjTQ9ciLB643J26jxu5kAbEXiuPL9Yz97QJ7jWawB-kBGm9XWHwK82dgj8uTLH3aUjBiP8-XP-V-lG_su |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkEovqNAH2wJ1pR6bksRONj6iBbS0LAcEEjfLTylVSdA-JHrpb-9MnFBxgAPX2E4sf5OZb-zxDMBX79JUyyJPjOQiETyUia54SIQ3ojBCetfVBpxdlNNr8eOmuFmDyXAXhsIqe90fdXqnrfsnh_1qHt7VNd3xRWeA-E7eERnUwxui4GOK6_v-93-cBxq8mDI8w7lg9yH1UBfk9cff31LWyjynw85xwZ8yT0_Rz84Mnb6BrZ4_sqM4xW1Y880ObE6Gsm078GrWn5a_hfq2viT5tKxuiBwu_IIh32MLClqPVSNYG5ihpiWzhP-c0U4-dmvZcXvfzleG3sX6aj7Moc8-j9Xr0eSx2fFlxlAC_Tu4Pj25mkyTvrRCYnkhl4kMyAyCd4VDCuZsqNCxyYTRFVp3I02qjU05z72XwnD8R70tMm0zo1NvyzxI_h7Wm7bxu8CkdVkVdJ45Z4Qw6KnLVAShM2-rcSj1CPJhRZXt845T-Yvfaggw-6U6GBTBoCIMI_j2MOgupt14vns5QKUeSY9Cw_D8wC8DsApxoiXWjW9XC0VJesRYoM4bwYeI-MNMkLRS2rjy40s_-xk2p1ezc3V-dvHzE7ymlhgNtAfry_nK7yPRWZqDTpD_AfAn-lY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=miR-200c+increases+the+sensitivity+of+breast+cancer+cells+to+Doxorubicin+through+downregulating+MDR1+gene&rft.jtitle=Experimental+and+molecular+pathology&rft.au=Safaei%2C+Sahar&rft.au=Amini%2C+Mohammad&rft.au=Najjary%2C+Shiva&rft.au=Mokhtarzadeh%2C+Ahad&rft.date=2022-04-01&rft.issn=1096-0945&rft.eissn=1096-0945&rft.volume=125&rft.spage=104753&rft_id=info:doi/10.1016%2Fj.yexmp.2022.104753&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-4800&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-4800&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-4800&client=summon |